mild to moderate Alzheimer’s.’
In a full double-blind study (nobody knows which patient gets which medication or placebo) the patients treated with Dimebon had a statistically significant improvement in all aspects including memory, daily living activities, and overall functioning.
This improvement showed up across the board at the 6 month mark and was more pronounced at the 12 month mark. At the end of the 12 month study, the Dimebon-treated patients had all preserved their starting points in functioning on all measures of the disease.’
The effect on the primary caregiver in the family was also noted with those caring for the treated group reporting less stress than those in placebo groups. The experiment points out that the caregivers in the treated group estimated they had saved one hour a day over the control group’s estimates of time spent giving care to the family member.
This drug would seem to hold a great deal of promise; so much so that the initial study was extended from 12 to 18 months and all placebo patients were switched to the drug by the end of the study.’
Research at the time of this report on Alzheimer medicine research is ongoing’
UPDATE – as of Feb 2010 – the latest trials came back indicating Dimbon wasn’t effective in the latest trials